TY - JOUR
T1 - Maintenance of neutralizing antibodies over ten months in convalescent SARS-CoV-2 afflicted patients
AU - Sonnleitner, Sissy Therese
AU - Prelog, Martina
AU - Jansen, Bianca
AU - Rodgarkia-Dara, Chantal
AU - Gietl, Sarah
AU - Schönegger, Carmen Maria
AU - Koblmüller, Stephan
AU - Sturmbauer, Christian
AU - Posch, Wilfried
AU - Almanzar, Giovanni
AU - Jury, Hanna
AU - Loney, Tom
AU - Tichy, Alexander
AU - Nowotny, Norbert
AU - Walder, Gernot
N1 - Funding Information:
We gratefully acknowledge the financial support of the Austrian Research Promotion Agency (FFG), Grant No. 35863961. The authors report no potential conflict of interest. We also thank DDI Martin Lamprecht, Stefanie Sonnleitner and Dominik B. C. Kopecky for excellent technical assistance and valuable suggestions.
Publisher Copyright:
© 2021 Wiley-VCH GmbH.
PY - 2022/5
Y1 - 2022/5
N2 - Knowledge of the level and duration of protective immunity against SARS-CoV-2 after primary infection is of crucial importance for preventive approaches. Currently, there is a lack of evidence on the persistence of specific antibodies. We investigated the generation and maintenance of neutralizing antibodies of convalescent SARS-CoV-2-afflicted patients over a ten-month period post-primary infection using an immunofluorescence assay, a commercial chemiluminescent immunoassay and an in-house enzyme-linked neutralization assay. We present the successful application of an improved version of the plaque-reduction neutralization assay which can be analysed optometrically to simplify data interpretation. Based on the results of the enzyme-linked neutralization assay, neutralizing antibodies were maintained in 77.4% of convalescent individuals without relevant decay over ten months. Furthermore, a positive correlation between severity of infection and antibody titre was observed. In conclusion, SARS-CoV-2-afflicted individuals have been proven to be able to develop and maintain neutralizing antibodies over a period of ten months after primary infection. Findings suggest long-lasting presumably protective humoral immune responses after wild-type infection.
AB - Knowledge of the level and duration of protective immunity against SARS-CoV-2 after primary infection is of crucial importance for preventive approaches. Currently, there is a lack of evidence on the persistence of specific antibodies. We investigated the generation and maintenance of neutralizing antibodies of convalescent SARS-CoV-2-afflicted patients over a ten-month period post-primary infection using an immunofluorescence assay, a commercial chemiluminescent immunoassay and an in-house enzyme-linked neutralization assay. We present the successful application of an improved version of the plaque-reduction neutralization assay which can be analysed optometrically to simplify data interpretation. Based on the results of the enzyme-linked neutralization assay, neutralizing antibodies were maintained in 77.4% of convalescent individuals without relevant decay over ten months. Furthermore, a positive correlation between severity of infection and antibody titre was observed. In conclusion, SARS-CoV-2-afflicted individuals have been proven to be able to develop and maintain neutralizing antibodies over a period of ten months after primary infection. Findings suggest long-lasting presumably protective humoral immune responses after wild-type infection.
KW - IgG antibodies
KW - SARS-CoV-2
KW - immunity
KW - neutralization test
KW - persistence
UR - http://www.scopus.com/inward/record.url?scp=85106588374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106588374&partnerID=8YFLogxK
U2 - 10.1111/tbed.14130
DO - 10.1111/tbed.14130
M3 - Article
C2 - 33960696
AN - SCOPUS:85106588374
SN - 1865-1674
VL - 69
SP - 1596
EP - 1605
JO - Transboundary and Emerging Diseases
JF - Transboundary and Emerging Diseases
IS - 3
ER -